Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although interleukin-1 receptor antagonist (IL-1Ra) treatment is associated with improved β-cell function and glycemic control in patients with type 2 diabetes, its role in the development of type 2 diabetes remains unclear. We used repeated measurements to characterize IL-1Ra trajectories in individuals who developed type 2 diabetes. RESEARCH DESIGN AND METHODS: This case-cohort study, nested within the Whitehall II cohort, was based on 335 incident type 2 diabetes cases and 2,475 noncases. We measured serum IL-1Ra levels at up to three time points per individual and estimated retrospective trajectories of IL-1Ra before diabetes diagnosis (case subjects) or end of follow-up (control subjects) using multilevel analysis. Models were adjusted for age, sex, and ethnicity. RESULTS: IL-1Ra levels were already higher in the case than control subjects 13 years before diabetes diagnosis/end of follow-up (mean [95% CI] 302 [290–314] vs. 244 [238–249] pg/ml). In control subjects, IL-1Ra levels showed a modest linear increase throughout the study period. In case subjects, IL-1Ra trajectories were parallel to those in control subjects until 6 years (95% CI 7.5–4.5) before diagnosis and then rose steeply to 399 (379–420) pg/ml at the time of diagnosis (P < 0.0001 for slope difference). Adjustment for BMI and waist circumference as time-varying covariates had little impact on these trajectories. CONCLUSIONS: We show elevated IL-1Ra levels for 13 years and an accelerated increase during the last 6 years before type 2 diabetes diagnosis, indicating the presence of an anti-inflammatory response that may act to counterbalance the metabolic and immunologic disturbances that precede type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most recent attempts to improve diabetes prediction using measurements from genetics and transcriptomics have not shown significant improvements in predictive performance but it is unknown whether serial measurements may decrease variations in non-genetic biomarkers allowing for a more precise estimation of their levels.34–36”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence
Singer, J. D., & Willett, J. B. (2003) · doi:10.1093/acprof:oso/9780195152968.001.0001 · Cited by 10,647
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493 · cited 1×
“However, it has been suggested that elevation of only IL-1 may not be sufficient to increase risk of type 2 diabetes; instead, increased IL-1 in combination with elevated levels of other proinflammatory cytokines may be required (28), thus limiting the predictive relevance of the IL-1Ra/IL-1 ratio without consideratio…”
BackgroundRelationship between Adipocyte Size and Adipokine Expression and Secretion
Skurk, T., Alberti-Huber, C., Herder, C., & Hauner, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1055 · Cited by 1,288 · cited 1×
“The finding that the difference in trajectories between case and control subjects could not be explained by obesity is important because adipose tissue is a major producer of IL-1Ra (9,29).”
BackgroundSelf-citationInsulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Cited by
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
“, with an accelerated increase in IL-1RA levels before the onset of T2”
BackgroundPrediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Self-citationAnti-inflammatory effects of exercise: role in diabetes and cardiovascular disease
Pedersen, B. K. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12781 · Cited by 617
Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490
A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes
Taylor, J. J., Preshaw, P. M., & Lalla, E. (2013) · Journal of Clinical Periodontology · doi:10.1111/jcpe.12059 · Cited by 425
“A number of clinical trials provide evidence for the utility of cytokine analysis in pre-clinical diagnosis of T2DM (Carstensen et al. 2010) and for cytokine blockade in therapy for T2DM (Larsen et al.”
BackgroundUusitupa, M., Hermansen, K., Savolainen, M. J., Schwab, U., Kolehmainen, M., Brader, L., Mortensen, L. S., Cloetens, L., Johansson‐Persson, A., Önning, G., et al. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12044 · Cited by 264
Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity
Stuart, M. J., & Baune, B. T. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.10.001 · Cited by 257
Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective
Wieser, V., Moschen, A. R., & Tilg, H. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0210-1 · Cited by 241
Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes
Grossmann, V., Schmitt, V. H., Zeller, T., Panova-Noeva, M., Schulz, A., Laubert-Reh, D., Juenger, C., Schnabel, R. B., Abt, T. G. J., Laskowski, R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-3008 · Cited by 257
“tions were reported to discriminate between individuals who finally developed type 2 diabetes compared with lower values in individuals who remained diabetes free (9,14,25,29,30).”
BackgroundInterleukin-1 (IL-1) family of cytokines: Role in Type 2 Diabetes
Banerjee, M., & Saxena, M. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.03.021 · Cited by 224
Novel biomarkers for prediabetes, diabetes, and associated complications
Dorcely, B., Katz, K., Jagannathan, R., Chiang, S. S., Oluwadare, B., Goldberg, I. J., & Bergman, M. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s100074 · Cited by 219
Moschen, A. R., Molnar, C., Enrich, B., Geiger, S., Ebenbichler, C. F., & Tilg, H. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00108 · Cited by 184
Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., Miller, J. W., Scherer, J. C., De Gaetano, A., Berg, J. K., & Landschulz, W. H. (2013) · Diabetes Care · doi:10.2337/dc12-1835 · Cited by 184
A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes
Taylor, J. J., Preshaw, P. M., & Lalla, E. (2013) · Journal of Periodontology · doi:10.1902/jop.2013.134005 · Cited by 204
“A number of clinical trials provide evidence for the utility of cytokine analysis in pre-clinical diagnosis of T2DM (Carstensen et al. 2010) and for cytokine blockade in therapy for T2DM (Larsen et al.”
BackgroundAnti‐inflammatory cytokines and risk of type 2 diabetes
Herder, C., Carstensen, M., & Ouwens, D. M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12155 · Cited by 170
“In the MONICA/KORA Study, low adiponectin levels were most 40 Herder et al. Volume 15 Suppl.”
BackgroundMethodResultSelf-citationBiomarkers for the Prediction of Type 2 Diabetes and Cardiovascular Disease
Herder, C., Karakas, M., & Koenig, W. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.93 · Cited by 168
Self-citationThe IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications
Herder, C., Dalmas, E., Böni-Schnetzler, M., & Donath, M. Y. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.08.001 · Cited by 168
Self-citationSteptoe, A., Hackett, R. A., Lazzarino, A. I., Bostock, S., La Marca, R., Carvalho, L. A., & Hamer, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410401111 · Cited by 167
The physiology of optimizing health with a focus on exercise as medicine
Pedersen, B. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114339 · Cited by 163
Prediabetes and associated disorders
Buysschaert, M., Medina, J. L., Bergman, M., Shah, A., & Lonier, J. (2014) · Endocrine · doi:10.1007/s12020-014-0436-2 · Cited by 183
A novel diabetes typology: towards precision diabetology from pathogenesis to treatment
Herder, C., & Roden, M. (2022) · Diabetologia · doi:10.1007/s00125-021-05625-x · Cited by 140
Self-citationInflammation in the Pathophysiology and Therapy of Cardiometabolic Disease
Donath, M. Y., Meier, D. T., & Böni-Schnetzler, M. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00002 · Cited by 124
Protein Biomarkers for Insulin Resistance and Type 2 Diabetes Risk in Two Large Community Cohorts
Nowak, C., Sundström, J., Gustafsson, S., Giedraitis, V., Lind, L., Ingelsson, E., & Fall, T. (2016) · Diabetes · doi:10.2337/db15-0881 · Cited by 120
Targeting the NLRP3 inflammasome–IL-1β pathway in type 2 diabetes and obesity
Meier, D. T., Souza, J. D. P., & Donath, M. Y. (2024) · Diabetologia · doi:10.1007/s00125-024-06306-1 · Cited by 133
Vistisen, D., Witte, D. R., Tabák, A. G., Herder, C., Brunner, E. J., Kivimäki, M., & Færch, K. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001602 · Cited by 106
“Interleukin 1 receptor antagonist (IL-1Ra) and total adiponectin serum concentrations were measured with the Quantikine ELISA kit (R&D Systems) in a diabetes case-cohort sample [5,6].”
MethodSelf-citationCytokines and Pancreatic β-Cell Apoptosis
Berchtold, L. A., Prause, M. C. B., Størling, J., & Mandrup-Poulsen, T. R. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.02.001 · Cited by 116
Action LADA Study Group, Pham, M. N., Hawa, M. I., Pfleger, C., Roden, M., Schernthaner, G., Pozzilli, P., Buzzetti, R., Scherbaum, W. A., Seißler, J., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2088-6 · Cited by 113
“Interestingly, the Whitehall II study on IL-1RA also reported an upregulation of both pro- and anti-inflammatory mediators 6 years before the diagnosis of type 2 diabetes [7, 8].”
BackgroundSelf-citationThe Nlrp3 inflammasome as a “rising star” in studies of normal and malignant hematopoiesis
Ratajczak, M. Z., Bujko, K., Cymer, M., Thapa, A., Adamiak, M., Ratajczak, J., Abdel-Latif, A. K., & Kucia, M. (2020) · Leukemia · doi:10.1038/s41375-020-0827-8 · Cited by 102
The Effect of Nutrition on Aging—A Systematic Review Focusing on Aging-Related Biomarkers
Leitão, C., Mignano, A., Estrela, M., Fardilha, M., Figueiras, A., Roque, F., & Herdeiro, M. T. (2022) · Nutrients · doi:10.3390/nu14030554 · Cited by 125
Hyperglycemia induces mixed M1/M2 cytokine profile in primary human monocyte-derived macrophages
Moganti, K., Li, F., Schmuttermaier, C., Riemann, S., Klüter, H., Gratchev, A. N., Harmsen, M. C., & Kzhyshkowska, J. G. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.07.006 · Cited by 94
Association of Subclinical Inflammation With Polyneuropathy in the Older Population
Herder, C., Bongaerts, B. W. C., Rathmann, W., Heier, M., Kowall, B., Koenig, W., Thorand, B., Roden, M., Meisinger, C., & Ziegler, D. (2013) · Diabetes Care · doi:10.2337/dc13-0382 · Cited by 88
Self-citationTimper, K., Grisouard, J., Sauter, N. S., Herzog-Radimerski, T., Dembinski, K., Peterli, R., Frey, D. M., Zulewski, H., Keller, U., Müller, B., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2012 · Cited by 88
“GIP (6-30) Insulin 100 nM - - + + + - + - +”
BackgroundZhao, G., Dharmadhikari, G., Maedler, K., & Meyer‐Hermann, M. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003798 · Cited by 95
Obesity, Inflammation, and Lung Injury (OILI): The Good
Wang, C. (2014) · Mediators of Inflammation · doi:10.1155/2014/978463 · Cited by 88
Differences in Biomarkers of Inflammation Between Novel Subgroups of Recent-Onset Diabetes
Herder, C., Maalmi, H., Strassburger, K., Zaharia, O.-P., Ratter, J. M., Karusheva, Y., Elhadad, M. A., Bódis, K., Bongaerts, B. W. C., Rathmann, W., et al. (2021) · Diabetes · doi:10.2337/db20-1054 · Cited by 73
Self-citationHerder, C., Ouwens, D. M., Carstensen, M., Kowall, B., Huth, C., Meisinger, C., Rathmann, W., Roden, M., & Thorand, B. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0879 · Cited by 73
Self-citationDiabetic Complications: An Update on Pathobiology and Therapeutic Strategies
Nellaiappan, K., Preeti, K., Khatri, D. K., & Singh, S. B. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210309104203 · Cited by 91
Herder, C., Færch, K., Carstensen‐Kirberg, M., Lowe, G. D. O., Haapakoski, R., Witte, D. R., Brunner, E. J., Roden, M., Tabák, Á. G., Mika Kivimaki, B., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0528 · Cited by 77
Self-citationThe potential of novel biomarkers to improve risk prediction of type 2 diabetes
Herder, C., Kowall, B., Tabák, Á. G., & Rathmann, W. (2013) · Diabetologia · doi:10.1007/s00125-013-3061-3 · Cited by 81
Self-citationTeichert, T., Vossoughi, M., Vierkötter, A., Sugiri, D., Schikowski, T., Schulte, T., Roden, M., Luckhaus, C., Herder, C., & Krämer, U. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083042 · Cited by 73
Self-citationThe cephalic phase of insulin release is modulated by IL-1β
Wiedemann, S. J., TRIMIGLIOZZI, K. A., Dror, E., Meier, D. T., Molina‐Tijeras, J. A., Rachid, L., Foll, C. L., Magnan, C., Schulze, F., Stawiski, M., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.001 · Cited by 72
Physiological role of cytokines in the regulation of mammalian metabolism
Baat, A. D., Trinh, B., Ellingsgaard, H., & Donath, M. Y. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.06.002 · Cited by 64
Luotola, K., Pietilä, A., Zeller, T., Moilanen, L., Kähönen, M., Nieminen, M. S., Kesäniemi, Y. A., Blankenberg, S., Jula, A., Perola, M., et al. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02294.x · Cited by 57
Inflammation in psychotic disorders: A population-based study
Suvisaari, J., Loo, B.-M., Saarni, S. E., Haukka, J. K., Perälä, J., Saarni, S. I., Viertiö, S., Partti, K., Lönnqvist, J. K., & Jula, A. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.07.006 · Cited by 63
“General population surveys have found that IL1RA predicts development of type 2 diabetes independently of CRP and other risk factors (Carstensen et al., 2010; Luotola et al., 2011), and is therefore a potentially valuable biomarker for identifying patients with high risk of type 2 diabetes.”
BackgroundAdiponectin Trajectories Before Type 2 Diabetes Diagnosis
Tabák, A. G., Carstensen, M., Witte, D. R., Brunner, E. J., Shipley, M. J., Jokela, M., Roden, M., Kivimäki, M., & Herder, C. (2012) · Diabetes Care · doi:10.2337/dc11-2263 · Cited by 55
“The present case-cohort study is based on a random sample from the source population who attended the phase 3 examination and were followed up to phase 7 (n = 8,816) (16).”
BackgroundMethodSelf-citationBuler, M., Aatsinki, S., Skoumal, R., Komka, Z., Tóth, M., Kerkelä, R., Georgiadi, A., Kersten, S., & Hakkola, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.302356 · Cited by 62
Hansen, C. S., Vistisen, D., Jørgensen, M. E., Witte, D. R., Brunner, E. J., Tabák, Á. G., Mika Kivimaki, B., Roden, M., Malík, M., & Herder, C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0634-3 · Cited by 53
“Serum levels of hsCRP, IL-6, IL-1Ra and total adiponectin were measured as described [14, 15].”
MethodSelf-citationChen, X., Sun, X., Wang, C., & He, H. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6660557 · Cited by 59
Inflammatory and Prothrombotic States in Obese Children of European Descent
Stoppa‐Vaucher, S., Dirlewanger, M., Meier, C. A., de Moerloose, P., Reber, G., Roux‐Lombard, P., Combescure, C., Saudan, S., & Schwitzgebel, V. (2012) · Obesity · doi:10.1038/oby.2012.85 · Cited by 56
“reported elevated IL-1Ra levels 13 years before the diagnosis of type 2 diabetes in adults (19).”
BackgroundBell, S., Mehta, G., Moore, K. P., & Britton, A. R. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12544 · Cited by 55
Marzi, C., Huth, C., Herder, C., Baumert, J. J., Thorand, B., Rathmann, W., Meisinger, C., Wichmann, H. ‐., Roden, M., Peters, A., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1514 · Cited by 51
“Prospective analyses on levels of A-SAA or time series studies as performed for other markers of subclinical inflammation (24) might further clarify the relationship between subclinical low-grade inflammation, postchallenge hyperglycemia, and incident type 2 diabetes.”
BackgroundSelf-citationIl-1β, Rage and Fabp4: Targeting the Dynamic Trio in Metabolic Inflammation and Related Pathologies
Hardaway, A., & Podgorski, I. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.90 · Cited by 52
Herder, C., Nuotio, M.-L., Shah, S., Blankenberg, S., Brunner, E. J., Carstensen, M., Gieger, C., Grallert, H., Jula, A., Kähönen, M., et al. (2014) · Diabetes · doi:10.2337/db14-0731 · Cited by 46
Self-citationTuomainen, T., Virtanen, J. K., Voutilainen, S., Nurmi, T., Mursu, J., de Mello, V. D., Schwab, U., Hakumäki, M. O. K., Pulkki, K. J., & Uusitupa, M. I. J. (2015) · Journal of Diabetes Research · doi:10.1155/2015/672653 · Cited by 47
“Elevated values of IL-1RA have also been shown to predict the onset of type 2 diabetes [22–24].”
BackgroundAnakinra treatment in patients with gout and type 2 diabetes
Vitale, A., Cantarini, L., Rigante, D., Bardelli, M., & Galeazzi, M. (2014) · Clinical Rheumatology · doi:10.1007/s10067-014-2601-7 · Cited by 47
“In this context, IL-1β results the pivotal cytokine involved in pancreatic beta cells inhibition and apoptosis as well as in the contribution to insulin resistance [6–9].”
BackgroundOu, Q., Zheng, Z., Zhao, Y., & Lin, W. (2019) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2019.1627515 · Cited by 51
“Persistent chronic inflammation not only induces symptoms of sickness but also plays surprisingly central roles in many serious chronic diseases, such as diabetes, obesity, atherosclerosis and rheumatoid arthritis (Hansson 2005; Carstensen et al. 2010; Solinas and Karin 2010; Aldayel et al. 2018).”
BackgroundHow biologics targeting the IL‐1 system are being considered for the treatment of type 2 diabetes
Böni‐Schnetzler, M., & Donath, M. Y. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04297.x · Cited by 42
IL-1 Receptor Antagonist (IL-1Ra) Levels and Management of Metabolic Disorders
Luotola, K. (2022) · Nutrients · doi:10.3390/nu14163422 · Cited by 53
IL-1 cytokine family members and NAFLD: Neglected in metabolic liver inflammation
Tilg, H., & Moschen, A. R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.007 · Cited by 46
“Elevated IL1b, IL-6, or IL-1Ra concentrations predict risk for type 2 diabetes in humans [17,18].”
BackgroundKnudsen, S. H., & Pedersen, B. K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0642-1 · Cited by 41
Tuomainen, M. H., Kärkkäinen, O. K., Leppänen, J., Auriola, S. O. K., Lehtonen, M., Savolainen, M. J., Hermansen, K., Risérus, U., Åkesson, B., Þórsdóttir, I., et al. (2019) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz179 · Cited by 46
Neuro-oncology family caregivers are at risk for systemic inflammation
Sherwood, P. R., Price, T. J., Weimer, J., Ren, D., Donovan, H. S., Given, C. W., Given, B. A., Schulz, R., Prince, J., Bender, C., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2083-3 · Cited by 37
“[38] reported significantly increased IL-1ra levels among persons who developed Type 2 diabetes at least 6 years prior to being diagnosed.”
Common biological mechanisms between bipolar disorder and type 2 diabetes: Focus on inflammation
Sharma, A. N., Bauer, I. E., Sanches, M., Galvez, J. F., Zunta‐Soares, G. B., Quevedo, J., Kapczinski, F. P., & Soares, J. C. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.06.005 · Cited by 38
Literature–Based Discovery of Salivary Biomarkers for Type 2 Diabetes Mellitus
Srinivasan, M., Blackburn, C., Mohamed, M., Sivagami, A. V., & Blum, J. S. (2015) · Biomarker Insights · doi:10.4137/bmi.s22177 · Cited by 42
Insulin analogues and cancer risk: the emergence of second-generation studies
Renehan, A. G. (2011) · Diabetologia · doi:10.1007/s00125-011-2352-9 · Cited by 33
Frühbeck, G., Catalán, V., Ramírez, B., Valentí, V., Becerril, S., Rodríguez, A., Moncada, R., Baixauli, J., Silva, C., Escalada, J., et al. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s354095 · Cited by 39
Herder, C., Kannenberg, J. M., Carstensen‐Kirberg, M., Huth, C., Meisinger, C., Köenig, W., Peters, A., Rathmann, W., Roden, M., & Thorand, B. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0498-6 · Cited by 30
“This explanation suggests similarities between IL-22 and IL-1RA, which also has diabetes- and atheroprotective effects, but higher circulating levels indicate a higher risk of type 2 diabetes and cardiovascular disease [25, 27, 28].”
BackgroundSelf-citationHerder, C., Kannenberg, J. M., Niersmann, C., Huth, C., Carstensen‐Kirberg, M., Wittenbecher, C., Schulze, M. B., Blüher, M., Rathmann, W., Peters, A., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0100 · Cited by 28
Self-citationFrühbeck, G., Catalán, V., Ramírez, B., Valentí, V., Becerril, S., Rodríguez, A., Moncada, R., Baixauli, J., Silva, C., Escalada, J., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 27
Strom, A., Kolb, H., Martin, S., Herder, C., Simon, M., Köenig, W., Heise, T., Heinemann, L., Roden, M., Schloot, N. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033108 · Cited by 25
“Increased levels of IL-6, IL-1RA, sICAM-1 and E-selection in the ‘‘high’’ CRP group are reminiscent of subclinical systemic inflammation seen in obesity, metabolic syndrome or type 2 diabetes [31,32,33,34].”
BackgroundSelf-citationHerder, C., Kannenberg, J. M., Huth, C., Carstensen‐Kirberg, M., Rathmann, W., Köenig, W., Strom, A., Bönhof, G. J., Heier, M., Thorand, B., et al. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3000 · Cited by 26
Self-citationUngvari, Z. I., Tabák, Á. G., Ádány, R., Purebl, G., Kaposvári, C., Fazekas‐Pongor, V., Csípő, T., Szarvas, Z., Horváth, K., Mukli, P., et al. (2023) · GeroScience · doi:10.1007/s11357-023-01018-7 · Cited by 33
Knock-Down of IL-1Ra in Obese Mice Decreases Liver Inflammation and Improves Insulin Sensitivity
Franck, N., Maris, M., Nalbandian, S., Talukdar, S., Schenk, S., Hofmann, H.-P., Bullough, D. A., & Osborn, O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107487 · Cited by 24
“Indeed, elevated systemic concentrations of IL-1Ra are associated with an increased risk of developing type 2 diabetes [15,16], and in retrospective studies this increase in IL-1Ra accelerated prior to type 2 diabetes diagnosis [17].”
BackgroundDiet, Inflammation and Prediabetes—Impact of Quality of Diet
Uusitupa, M. I. J., & Schwab, U. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.029 · Cited by 30
Chaar, D., Dumont, B. L., Vulesevic, B., Neagoe, P.-E., Räkel, A., White, M., & Sirois, M. G. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.05.026 · Cited by 22
Bergman, M., Dankner, R. S., Roth, J., & Narayan, K. M. V. (2013) · Endocrine · doi:10.1007/s12020-013-9873-6 · Cited by 25
de Mello, V. D., Dahlman, I. A., Lankinen, M. A., Kurl, S., Pitkänen, L., Laaksonen, D. E., Schwab, U., & Erkkilä, A. T. (2019) · Nutrition and Diabetes · doi:10.1038/s41387-018-0069-2 · Cited by 22
Luotola, K., Piltonen, T. T., Puurunen, J., Morin-Papunen, L. C., & Tapanainen, J. S. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1342793 · Cited by 21
Novel Biomarkers of Inflammation for the Management of Diabetes: Immunoglobulin-Free Light Chains
Matsumori, A. (2022) · Biomedicines · doi:10.3390/biomedicines10030666 · Cited by 23
Bell, S., & Britton, A. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1845 · Cited by 22
Wium, C., Eggesbø, H. B., Ueland, T., Michelsen, A. E., Torjesen, P. A., Aukrust, P., & Birkeland, K. I. (2014) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2014.953571 · Cited by 19
Bohl, M., Bjørnshave, A., Gregersen, S., & Hermansen, K. (2016) · The Review of Diabetic Studies · doi:10.1900/rds.2016.13.148 · Cited by 22
Treatment of type 2 diabetes mellitus in the elderly – Special considerations
Gadó, K., Tabák, Á. G., Vingender, I., Domján, G., & Dörnyei, G. (2024) · Physiology International · doi:10.1556/2060.2024.00317 · Cited by 27
El-Gharib, M., FARAHAT, M. N. M. R., Mahfouz, A., & Morad, M. A. (2013) · Journal of Basic and Clinical Reproductive Sciences · doi:10.4103/2278-960x.112582 · Cited by 22
“Most attempts to substantially improve diabetes prediction with measurements from genetics and transcriptomics have not been successful, and whether serial measurements might decrease variations in non-genetic biomarkers, resulting in a more precise estimation of their concentrations, is not known.[22-24]”
BackgroundRamenzoni, L. L., Zuellig, R. A., Hussain, A., Lehmann, R., Heumann, C., Attin, T., & Schmidlin, P. R. (2018) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3408-7 · Cited by 19
The alarm secretory leukocyte protease inhibitor increases with progressive metabolic dysfunction
López‐Bermejo, A., Ortega, F. J., Castro, A., Ricart, W., & Fernández‐Real, J. M. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.02.037 · Cited by 18
Inflammation in human adipose tissues–Shades of gray, rather than white and brown
Rakotoarivelo, V., Variya, B. C., Ilangumaran, S., Langlois, M., & Ramanathan, S. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.10.001 · Cited by 16
Molecular Aspects of Lifestyle and Environmental Effects in Patients With Diabetes
Nayor, M. G., Shah, S. H., Murthy, V. L., & Shah, R. V. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.070 · Cited by 13
Teichert, T., Vossoughi, M., Vierkötter, A., Sugiri, D., Schikowski, T., Hoffmann, B. H., Schulte, T., Roden, M., Raulf, M., Luckhaus, C., et al. (2014) · Environmental Research · doi:10.1016/j.envres.2014.06.021 · Cited by 13
Self-citationKolb, H., Lückemeyer, K., Heise, T., Herder, C., Schloot, N. C., Köenig, W., Heinemann, L., Martin, S., & on behalf of the DIATOR Study Group (2013) · PLoS ONE · doi:10.1371/journal.pone.0072440 · Cited by 12
“In a large case-chort and a population-based study similar results were obtained for IL-1 RA and IL-6, respectively, but not for CRP [46,42].”
ResultSelf-citationAmaral, G. A., Alves, J. D., Honório‐França, A. C., Fagundes, D. L. G., Araújo, G. G., Lobato, N. S., Lima, V. V., & Giachini, F. R. C. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666191116141159 · Cited by 12
IL ‐1 receptor antagonist levels are associated with glucose tolerance in polycystic ovary syndrome
Luotola, K., Piltonen, T., Puurunen, J., & Tapanainen, J. S. (2016) · Clinical Endocrinology · doi:10.1111/cen.13077 · Cited by 12
Ghalishourani, S. S., Farzollahpour, F., Shirinbakhshmasoleh, M., Kolahdouz, S., Ghaedi, E., Behrouzian, M., Haghighian, H. K., Campbell, M. S., Asbaghi, O., & Moodi, V. (2021) · Phytotherapy Research · doi:10.1002/ptr.7120 · Cited by 11
“…by the activation of immune-related cells and the release of several pro-inflammatory cytokines, such as C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6) (Aldayel et al., 2018; Carstensen et al., 2010; Solinas & Karin, 2010) (Takeuchi & Akira, 2010).”
BackgroundNaqvi, F., Dastagir, N., & Jabeen, A. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-03837-9 · Cited by 15
Kim, M., Cho, Y. K., Jung, C. H., & Lee, W. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111125 · Cited by 10
Abildgaard, J., Johansen, M. Y., Skov‐Jeppesen, K., Andersen, L. B., Karstoft, K., Hansen, K. B., Hartmann, B., Holst, J. J., Pedersen, B. K., & Ried‐Larsen, M. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002776 · Cited by 9
Nagrani, R., Foraita, R., Wolters, M., Henauw, S. D., Mårild, S., Molnár, D., Moreno, L. A., Russo, P., Tornaritis, M. J., Veidebaum, T., et al. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3511 · Cited by 10
Tronko, M. D., & Kp, Z. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.6.2019.185403 · Cited by 8
Serum Uric Acid: A Novel Risk Factor for Gestational Diabetes Mellitus
Singh, U., Mehrotra, D. S., Singh, D. R., Sujata, D. S., Gangwar, M. L., & Shukla, B. (2015) · International Journal of Medical Research and Review · doi:10.17511/ijmrr.2015.i1.03 · Cited by 7
Lischka, J., Schanzer, A., de Gier, C., Greber‐Platzer, S., & Zeyda, M. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156372 · Cited by 9
Metadata
- Authors
- Carstensen, M., Herder, C., Kivimäki, M., Jokela, M., Roden, M., Shipley, M. J., Witte, D. R., Brunner, E. J., & Tabák, A. G.
- Affiliations
- Deutsches Diabetes-Zentrum e.V. (DE)
- Department of Epidemiology and Public Health, University College London, London, U.K.;
- University College London (GB)
- Düsseldorf University Hospital (DE)
- Corresponding author
- Herder, Christian
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-02-25
- Volume
- 59
- Issue
- 5
- Pages
- 1222-1227
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2857902
- OpenAlex
- W2126985857
- Cited by
- 137
- References
- 38
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 11 · 2015: 10 · 2014: 16 · 2013: 16 · 2012: 10
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- John D. and Catherine T. MacArthur Foundation
- British Heart Foundation (RG/07/008/23674)
- Bupa Foundation
- Health and Safety Executive
- Academy of Finland
- Bundesministerium für Gesundheit
- Novo Nordisk
- National Institutes of Health
- Agency for Healthcare Research and Quality (HS06516)
- Medical Research Council
- Economic and Social Research Council
- National Institute on Aging (AG 13196, R37AG013196, R01AG013196)
- National Heart, Lung, and Blood Institute (R01HL036310)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- interleukin-1 receptor antagonist, type 2 diabetes, prediabetes, serum biomarkers, biomarker trajectories, anti-inflammatory response, inflammation, beta-cell function, Whitehall II cohort
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Cohort Studies, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.